Japan Said Set To Reject Court-Proposed Iressa Suit Settlement
This article was originally published in PharmAsia News
Executive Summary
Japan's government is expected to side with AsraZeneca KK and reject a proposal by two district courts to settle class-action suits concerning the Iressa (gefitinib) lung-cancer drug